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Summary
Misfolding and toxic accumulation of _-synuclein is
thought to cause Parkinson’s disease. Developing
ways to reduce α-Synuclein accumulation may lead
to future treatments. The dominant model of _-
synuclein degradation is by the proteasome
degradation pathway where _-synuclein toxicity has
been associated with malfunctions in this pathway.
However, evidence is building to suggest that the
multivesicular body (MVB) sorting pathway to
degradation via the vacuole/ lysosome also
degrades _-synuclein and that malfunctions in this
pathway lead to _-synuclein accumulation and
toxicity.  Here we demonstrate that the absence of
vps28, an essential component of the MVB sorting
pathway, increases the toxicity of both wild type
and mutant forms of _-synuclein.  The absence of
vps28 also significantly alters the cellular
distribution and localization of _-synuclein and
increases its cytoplasmic aggregation.  We propose
that dysfunction of the MVB sorting pathway to the
vacuole/lysosome can lead to the pathology linked
to Parkinson’s disease, including cell death.
Introduction
Parkinson’s Disease (PD), the most common
neurodegenerative disorder, is physically characterized
by slowed movement, resting tremor, muscular rigidity,
and postural instability (Giasson and Lee, 2003).  One
defining quantitative feature of PD is the death of
dopaminergic neurons in the substantia nigra, which
normally function to produce the neurotransmitter
dopamine that is responsible for smooth, coordinated
muscle movement (Forno, 1996).  Within dying neurons
are cytoplasmic inclusions of misfolded _-synuclein
called Lewy bodies and the associated abnormal
neurons called Lewy neurites in some of the remaining
neurons of the same region (Goedert, 2001; Vekrellis et
al., 2004; Spillantini et al., 1998).
_-Synuclein is a cytoplasmic, membrane
associated protein of 140 amino acids abundant at
presynaptic terminals in the nervous system (Goedert,
1997; Davidson et al., 1998; McLean et al., 2000).
While the precise function of _-synuclein remains
unknown, it has been implicated in synaptic remodeling
and plasticity (Kahl et al., 2000). The three missense
point mutations of the _-synuclein gene on
chromosome 4, A30P, A53T and E46K, associated with
familial PD may result in the misfolding and fibril
formation of the _-synuclein protein and its subsequent
aggregation into Lewy bodies (Goedert, 2001;
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Nussbaum and Polymeropoulos, 1997; Kruger et al.,
1998; Conway, 1998; Zarranz, 2004).  Increasingly,
evidence shows that abnormalities in the degradation of
misfolded _-synuclein underlie the toxic affects seen in
PD but the precise nature of this degradation remains
uncharacterized (McNaught et al., 2001).
One avenue of possible treatment for PD
focuses on clearing these misfolded proteins from cells.
Genetic evidence shows that _-synuclein is degraded
by the ubiquitin-proteasome degradation pathway
(Bennet et al., 1999; Holtz and O’Malley, 2003).  Under
normal circumstances, misfolded proteins, including
misfolded _-synuclein, are targeted to the proteasomal
degradation pathway by polyubiquitination (Thrower et
al., 2000).  Also, several genetic mutations associated
with PD inhibit elements of the ubiquitin-proteasome
degradation pathway including mutations in Parkin on
chromosome 6, which normally functions as an
ubiquitin ligase, PARK 3 on chromosome 2, and in
ubiquitin C-terminal hydrolase L1 (Ceichanover and
Brundin 2003; McNaught et al., 2002).  This evidence
points to the ubiquitin-proteasome degradation pathway
as the mechanism for _-synuclein degradation and that
malfunctions in this pathway play a major role in PD.
However, pharmacological studies indicate
that proteasome inhibitors do not alter cellular levels of
_-synuclein or Parkin (Rideout and Stefanis, 2002;
Biasini et al., 2004).  In fact, _-synuclein aggregation
has been implicated as a causative agent in dysfunction
of the ubiquitin-proteasome system as apposed to
dysfunction in the system causing _-synuclein
aggregation (Snyder et al., 2003).  Therefore, a system
other than the ubiquitin-proteasome degradation
pathway is implicated in the breakdown of _-
synuclein—the vacuole/lysosome pathway.
The vacuole/lysosome has its own system of
targeting and transport and typically degrades
extracellular particles, worn out organelles, and
membrane proteins, a category including _-synuclein.
Ubiquitination, in this case monoubiquitination, has
been shown to sufficiently target proteins to endocytic
degradation pathways, such as the multivesicular body
(MVB) sorting pathway, to the vacuole/lysosome
(Hochstrasser, 1996; Katzmann et al., 2001).  Recently,
in mammalian cells, some _-synuclein translocates to
lysosomes for degradation and lysosomal inhibitors
have been shown to increase the intracellular levels of
_-synuclein (Cuervo et al., 2004; Lee et al., 2004).
The MVB pathway is composed by a number
of essential vacuolar protein sorting proteins (vps
proteins) required (Odorizzi et al., 1998) which either
function alone or as part of a complex.  One such
complex is the Endosomal Sorting Complex Required
for Transport 1 (ESCRT 1), a 350 kDa complex
composed of vps23, vps28, and vps37 (Katzmann et
al., 2001).  The specific role of vps28 (human ortholog
hvps28) has yet to be characterized, though it has been
implicated as necessary for vps23 function (Bishop and
Woodman, 2001), the ESCRT 1 component that binds
Ub (Katzmann et al., 2001; Babst et al., 2000).  We
propose that _-synuclein is targeted to the MVB sorting
pathway for degradation by the vacuole/lysosome and
vps28 is a required element for the functioning of this
pathway.  Therefore, it can be conjectured that the
absence of a functioning vps28 gene would lead to
disruptions in the MVB sorting pathway and therefore
degradation by the vacuole/lysosome.  The disruption
of degradation would lead to an accumulation of
proteins, including _-synuclein, which is linked to _-
synuclein toxicity and PD symptoms.
To gain understanding of the role of vps28 in
_-synuclein degradation and toxicity, a number of in
vivo experiments were performed using a S. cerevisiae
PD model developed in our lab (Johnson et al., 2003;
Sharma et al., 2004) as yeast has already proven to be
a useful model for studying neurodegenerative
diseases, including Alzheimer's and Huntington’s
Disease in addition to PD (Outeiro and Muchowski,
2004; Outeiro and Lindquist, 2003).  In vps28 deficient
S. cerevisiae mutants, wild type _-synuclein toxicity has
been shown to be greater than in cells with an intact
genome (Willingham et al., 2003).  We assessed the
toxicity of wild type and mutant _-synucleins (A30P,
A53T, and A30P/A53T) through growth curve analysis
and dilution series spotting of strains both with and
without vps28.  The cellular distribution and
accumulation of wild type and mutant _-synucleins in
these strains were assessed through GFP microscopy
and biochemical assessment was used to examine wild
type _-synuclein’s expression, accumulation, and
stability in vivo over time.  Together these assays
construct a clearer model of the role of vps28 in α-
synuclein degradation and toxicity.
Results
_- synuclein is expressed in vps28 strains
Vps28 was previously identified by a genetic screen to
enhance the toxicity of wild type _-synuclein in S .
cerevisiae (Willingham, et al., 2003).  In order to further
examine the affects of _-synuclein in vitro, S. cerevisiae
parent wild type and vps28 strains were transformed
with wild type _-synuclein, A30P _-synuclein, A53T α-
synuclein, and A30P/A53T _-synuclein tagged with
GFP (green fluorescence protein).  Control
transformants with empty pYES2 parent plasmid and
GFP alone were also created.  Galactose-induced _-
synuclein expression was verified via western blotting
(Figure 1a).  No _-synuclein expression was seen in
cells transformed with the empty pYES2 parent vector
_-synuclein (Figure 1a, lanes 1-2) nor cells containing
the wild type _-synuclein gene grown in non-inducing
glucose media (Figure 1a, lanes 5-6).  For all _-
synuclein transformants a single band was detected at
approximately 58 kDa, corresponding to the monomeric
form of _-synuclein tagged with GFP, when expression
was induced by galactose (Figure 1a, lanes 4-14).
Band intensity does not remain consistent between
v p s 2 8  transformants and their parent strain
counterparts for mutant _-synucleins A30P, A53T, and
A30P/A53T.  However, these differences are not
accounted for by variation in protein quantity as
visualized by coomassie staining (Figure 1b).  For
A30P, and A30P/A53T _-synuclein mutants, band
intensity was weaker for vps28 transformants though
more protein was present in the sample.  This indicates
that the absence of vps28 has a mild but consistent
affect on mutant _-synuclein expression.
Vps28 modestly increases α-synuclein toxicity
To asses the impact of the lack of vps28 on growth of
_-synuclein expressing cells, parent strain and vps28
comparative growth curves were established for each
construct (Figure 2a).  For pYES2 parent plasmid    and
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Figure 1. _-Synuclein Expression in Vps28
(A) Western blotting.  All parent strain and vps28 _-synuclein
transformants showed a band at approximately 58kDa
corresponding to _-synuclein expression when induced by
galactose (lanes 7-14).  No expression was seen in glucose
grown _-synuclein transformants (lanes 5-6) nor cells
containing only the pYES2 parent vector (lanes 1-2).  GFP
transformants produced a band at approximately 36kDa which
corresponds to GFP expression when induced by galactose
(lane 4). (B) Coomassie Staining.  All lanes exhibit the same
number of bands at comparable intensities indicating that the
same amount of protein was loaded for each sample.
Variances in intensity do not correlate with the amount of _-
synuclein expression indicated by band intensity on the western
blot.
GFP transformants, growth of vps28 and parent strains
was equivalent, with vps28 exhibiting only slightly
slowed growth in the pYES2 transformant.All vps28 α-
synuclein (both wild type and mutant forms)
transformants exhibited slowed growth compared to
parent strain when _-synuclein expression was
induced.  The most significant slowed growth was
present in vps28 wild type _-synuclein transformants.
To further examine _-synuclein toxicity, dilution series
spotting of parent strain and vps28 transformants was
plated on inducing and non-inducing media (Figure 2b).
In the absence of induction, the growth of all parent
strain and vps28 transformant pairs was comparable.
When _-synuclein expression was induced, the wild
type vps28 transformant exhibited notably less growth
than the wild type parent strain transformant.  Only a
marginal difference in growth was seen in vps28 A30P,
A53T, and A30P/A53T _-synuclein transformants, when
compared to their parent strain counterparts.  No
difference was seen between the growth of parent
strain and vps28  pYES2 or GFP transformants.
Together, growth curve and spotting data indicate that
the absence of the vps28 gene definitively increases
wild type _-synuclein toxicity in S. cerevisiae while
mutant _-synuclein is only marginally more toxic.
Vps28 alters _-synuclein localization and increases
peri-vacoular aggregation
To analyze the localization of _-synuclein, _-synuclein-
GFP fusion transformants were visualized through
fluorescence microscopy (Figure 3). In wild type and
A53T _-synuclein parent strain cells, the _-synuclein-
GFP fusion localizes at the plasma membrane which is
consistent with _-synuclein’s characterization as a
membrane associated protein and previous microscopy
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Figure 2. _-Synuclein Toxicity Assessment in Vps28
(A) Growth curve. Comparative growth curves were established using OD600 for transformants with an intact vps28 gene and those
without vps28.  In the absence of _-synuclein expression, both strains showed comparable growth while _-synuclein expression resulted in
slightly inhibited growth of the vps28 transformants with wild type _-synuclein exhibiting the most significant difference.  (B) Serial spotting
on plates. Growth was also analyzed by five fold serial dilution spotting of transformed yeast cells on non-inducing (glucose) or inducing
(galactose) SC-ura plates.  In the absence of _-synuclein expression, growth of all transformants was comperable.  However, _-synuclein
expression caused minor toxic effects in the wild type vps28 transformant when compared to the wild type parent strain transformant.  Little
or no difference in growth was seen between other parent strain and vps28 transformants when _-synuclein expression was induced.
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Figure 3. _-Synuclein Cellular Distribution and Accumulation in Vps28
After 24 hours of induction, _-synuclein-GFP exhibited peripheral localization in parent strain wild type and A53T _-synuclein transformants
while _-synuclein-GFP showed cytoplasmic distribution in A30P and A30P/A53T _-synuclein transformants, as previously shown.  At the
same time point, vps28 wild type _-synuclein transformant exhibited _-synuclein distribution throughout the cytoplasm, foci of accumulation,
and exclusion from the vacuole.  While the A30P _-synuclein vps28 transformant remained distributed throughout the cytoplasm, foci of
cytoplasmic accumulation were also seen.  Both A53T and A30P/A53T _-synuclein transformants exhibited _-synuclein distribution
throughout the cytoplasm and distinct foci of accumulation.  All vps28 transformants exhibited markedly different _-synuclein distribution
and an increase in accumulation when compared to their parent strain counterparts.
findings (Davidson, et al., 1998; Outeiro and Lindquist,
2003).  Also consistent with the same previous model,
A30P _-synuclein parent strain cells exhibited _-
synuclein-GFP dispersion throughout the cytoplasm,
reflecting A30P _-synuclein’s poor membrane binding
ability (Outeiro and Lindquist, 2003).  This decreased
affinity for membrane binding also leads to the cytosolic
distribution of A30P/A53T _-synuclein-GFP in parent
strain cells.  Notably, cells exhibiting cytoplasmic
distribution (A30P and A30P/A53T), _-synuclein-GFP
was excluded from the vacuole and in all transformants
no cytoplasmic inclusions are seen.
In wild type and A53T vps28 cells, _-
synuclein-GFP lacked the expected membrane
association and exhibited cytoplasmic distribution
instead.  Prominent cytoplasmic inclusions, appearing
as foci of fluorescence, are also present in close
proximity to the vacuole (indicated by white arrows in
Figure 3) from which _-synuclein-GFP remains
excluded.  A30P and A30P/A53T _-synuclein vps28
cells still exhibited _-synuclein-GFP dispersion
throughout the cytoplasm but _-synuclein-GFP
localized into numerous cytoplasmic inclusions, again in
the vicinity of the _-synuclein-GFP excluding vacuole.
In the absence of the vps28 gene, all forms of _-
synuclein-GFP accumulate in the cytoplasm and form
distinct inclusions in the vicinity of the vacuole, which
excludes _-synuclein-GFP.  This localization is
dramatically different from localization in the presence
of the vps28 gene.
α-Synuclein turnover unchanged in vps28
To asses the affect of vps28 absence on the
persistence and stability of _-synuclein in cells, the
cellular expression of _-synuclein was halted after 24
hours by transfer from inducing galactose media to non-
inducing glucose media and _-synuclein levels were
monitored for the following 24 hours (Figure 4).  In cells
with an intact vps28 gene, _-synuclein was detected at
all time points during the 24 hour time course and no
consistent decrease in _-synuclein presence was seen
as indicated by the presence of bands at each time
point.  Inconsistencies in band intensity seen for cells
with vps28 (lanes for 0, 0.5, and 1 hours for example)
are a result of variances in the amount of total protein
present in the samples (data not shown).  In vps28
cells, there was also no significant decrease in the
amount of _-synuclein present in cells up to 24 hours
after the loss of induction.  The slight decrease seen
between 0.5 and 1 hours in vps28 cells, which may
indicate that _-synuclein is degraded in absence of
vps28. No bands appeared above the 58 kDa size,
corresponding to the monomeric form of α-synuclein
tagged with GFP, for any of the samples.
Discussion
As _-synuclein misfolding and dysfunctions in its
degradation persists as an underlying cause of PD,
studying _-synuclein degradation in vivo is of critical
import (McNaught et al., 2001). Recent studies have
implicated that the vacuolar/lysosomal system of
degradation in the breakdown of _-synuclein (Cuervo et
al., 2004; Lee et al., 2004; Willingham, et al., 2003).
One important pathway to the vacuole/lysosome, the
MVB pathway, is composed of a plethora of vps
proteins (Odorizzi et al., 1998).  The absence of vps28,
as a part of the ESCRT-I complex, has been shown to
increase α-synuclein toxicity, implying that vps28 plays
a  role  in  the  clearance  of  _-synuclein  from  the  cell
(Willingham, et. al. 2003). We provide insight into _-
synuclein degradation.  Specifically our data suggests
that _-synuclein may utilize the vacuole/lysosome
pathway in addition to the proteasome degradation
pathway.
Vps28 prevents α-Synuclein from being toxic to
yeast
An increase in wild type _-synuclein toxicity has
previously been demonstrated in vps28  in vivo
(Willingham, et. al., 2003).  We also demonstrate an
increase in the toxicity of wild type _-synuclein in vps28
cells though the increase in toxicity was more
moderate.  This could be because our cells may
express _-synuclein at lower levels than those used in
the Willingham et. al., 2003 study.  We extended this
research by examining _-synuclein toxicity in _-
synuclein mutants and demonstrated that the toxicity of
A30P, A53T, and A30P/A53T mutant _-synuclein was
also modestly increased in the absence of vps28.  It
was expected that toxicity would be greater in than our
experiments demonstrated, especially for _-synuclein
mutants when compared to wild type.  The absence
variation in toxicity between wild type and mutant _-
synucleins implies that the absence of vps28 is
responsible for toxicity exclusively and not mutations in
_-synuclein itself.  This explains the sporadic
occurrence of PD in patients that do not have _-
synuclein mutations, tying sporadic PD to the
accumulation of _-synuclein due to dysfunctions in the
vacuolar/lysosomal degradation pathway.
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Figure 4. Biochemical assessment of wild type _-synuclein accumulation in vps28
Over a course of 24 hours after the halting of wild type a-synuclein synthesis, the in vivo levels of a-synuclein did not decline in the parent
strain nor vps28.  There was no apparent difference between the levels of wild type a-synuclein in parent strain cells and vps28 cells
throughout the time course.  This indicates that the presence of vps28 does not have a discernable affect on the clearance of a-synuclein
from cells 24 hours after a-synuclein expression is stopped.
α-Synuclein may be targeted to the MVB pathway
The finding that the absence of vps28 significantly
alters the localization of all _-synuclein forms and
increases the amount of _-synuclein cytoplasmic
inclusion allowed us key insight into the role of vps28 in
_-synuclein degradation.  The accumulation of _-
synuclein into Lewy bodies within cells has been
previously linked to cell death via the disruption of a
variety of cellular processes (Goedert, 2001; Vekrellis
et al., 2004; Spillantini et al., 1998).  The presence of
cytoplasmic inclusions of all forms of _-synuclein in
vps28 cells implies that the absence of vps28 leads to
the accumulation of _-synuclein within the cell, a key
aspect of PD.  This dramatic difference seen in the
localization of all forms of _-synuclein between cells
with the vps28 gene and cells without indicates that
vps28 is key in the removal of _-synucleins from the
cell.  As an integral part of the MVB sorting pathway to
the lysosome, the affect of vps28 on _-synuclein
behavior points to the importance of the MVB pathway
and the lysosome in _-synuclein degradation.
Vps28 presence does not discernibly alter _-
synuclein clearance
The presence of vps28 did not have discernable affect
on the presence of wild type _-synuclein up to 24 hours
after the _-synuclein expression was halted.  The
persistence of wild type _-synuclein in cells of both
parent strain and vps28 may be due to the fact that _-
synuclein may be present in SDS-soluble aggregates
which broke down to monomers in sample buffer in
both parent and vps28 strains.  This would explain the
consistency of band size at 58 kDa.  Also, alpha
synuclein is a reasonably stable protein in yeast and
the lack of vps28 may not be enough to increase this
stability by a large, discernable amount.  Therefore, the
rate of disappearance from yeast cytosol would appear
similar in cells with and without vps28.  Vps28 may
impact wild type _-synuclein stability, but its effects may
not be dramatic enough to capture in this assay.
Role of Vps28 in _-synuclein Biology
In this study we demonstrate that vps28, as an
essential part of the MVB sorting pathway to the
vacuole/lysosome, plays an integral role in the
clearance of all forms of _-synuclein from the cell and
that cells lacking vps28 experience an increase in _-
synuclein accumulation within the cell.  This
accumulation, we propose, explains the toxic affects of
_ -synuclein.
The misfolding of _-synuclein and the
subsequent formation of Lewy bodies has been linked
to cell death in PD (Goedert, 2001; Vekrellis et al.,
2004; Spillantini et al., 1998).  The ubiquitin-
proteasome degradation pathway has been shown to
degrade misfolded _-synuclein (Bennet et al., 1999;
Holtz and O’Malley, 2003) and dysfunction of this
pathway has been linked to _-synuclein accumulation
and aggregation (Sharma, 2004).  However, the
function of the ubiquitin-proteasome in clearing _-
synuclein from the cell has been brought into question,
implicating an alternate method of _-synuclein
degradation (Rideout and Stefanis, 2002; Biasini et al.,
2004).  Conveniently, _-synuclein has also been shown
to be targeted to and degraded by the
vacuole/lysosome (Cuervo et al., 2004; Lee et al.,
2004).
Essential to the degradation of proteins by
the vacuole/lysosome is the MVB sorting pathway, of
which vps28 is a component (Katzmann et al., 2001).
Our data shows that disruption of this pathway, via the
absence of the vps28, elevates the toxicity of all forms
of _-synuclein in addition to increasing its accumulation
and aggregation within cells.  This indicates that
disruption of the MVB sorting pathway and therefore
transport to the vacuole/lysosome for degradation has
similar affects as the disruption of the ubiquitin-
proteasome degradation pathway (Snyder et al., 2003,
McNaught, et. al., 2003).  Therefore, we propose a
model of _-synuclein degradation in which it can be
targeted to either the proteasome, targeted by
polyubiquitination (Thrower et al., 2000), or the
vacuole/lysosome, targeted by monoubiquitination
(Hochstrasser, 1996; Katzmann et al., 2001), for
degradation depending on its ubiquitination state
(Figure 5).  It is likely that these pathways work in
conjunction to clear _-synuclein from the cell and that
disruption of either of these pathways can cause
accumulation of _-synuclein, disruption of cellular
processes, and eventually cell death as seen in PD.
Future research could be conducted to
understand the role of other vps proteins in _-synuclein
clearance from the cell through the vacuole/lysosome
degradation pathway to understand how regulation of
vesicular transport could be used to treat PD.  Also,
confirmation of the ubiquitination state of _-synuclein in
vps28 would point to how _-synuclein is selected for
degradation by the two main degradation machineries,
the proteasome or the lysosome.
Experimental Procedures
Strains and Transformation
Human wild type and A53T mutant _-synuclein cDNAs were a
gift from Christopher Ross (Johns Hopkins University).  A30P
and A30P/A53T mutant _-synuclein were created using site
directed mutagensis (Invitrogen) from wild type and A53T
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Figure 5. Model for the effects of vps28 on _-synuclein toxicity
Previous research has established that misfolded _-synuclein is polyubiquitinated and degraded by the ubiquitin-proteasome system.
Emerging evidence indicates that _-synuclein is also degraded by the vacuole/lysosome, with monoubiquitination being the possible
targeting mechanism for this pathway.  Together, both of these pathways could operate in conjunction to clear misfolded _-synuclein from
the cell Dysfunction in either of these pathways could disrupt this clearance and lead to _-synuclein accumulation and subsequent cell
death associated with PD.
mutant _-synuclein, respectively.  Wild type and mutant _-
synuclein cDNAs were subcloned into the pcDNA3.1
expression  vector,  which  were  then  amplified and subcloned
into the pYES2.1/V5-His-Topo yeast expression vector
(Invitrogen).  α -Synuclein expression plasmids were
transformed as described (Burke, 2000) into URA-3 deficient S.
cerevisiae 4741 and vps28 strains.  For selection, yeast cells
were  grown  on  synthetic-complete  media  lacking  uracil (SC-
ura).  Presence of α-synuclein constructs was confirmed by
polymerase chain reaction.  The pYES2.1 vector, containing a
galactose inducible promoter (GAL1), allowed for regulated _-
synuclein expression. Table I lists the transformed yeast strains
used in this study.
Western Blotting
Yeast cells (2.5x107 cells/ml) were washed in 50mM Tris (pH
7.5), 10mM Nan3 and solubilized Electrophoresis Sample Buffer
(ESB, Burke, 2000) containing 2% SDS, 80mM Tris (pH 6.8),
10% glycerol, 1.5% DTT, 1mg.ml bromophenol blue, and a
cocktail of protease inhibitors and solubilizing agents (1%
Triton-X 100, 1mM PMSF, 1mM benzamidine, 1mM sodium
orthovanadate, 0.7_g/ml pepstatin A, 0.5_g/ml leupeptin,
10_g/ml E64, 2_g/ml aprotinin, and 2_g/ml chymostatin).
Samples were run on pre-cast 10-20% Tris-Glycine SDS gels
(Invitrogen), using SeeBlue as the molecular standard
(Invitrogen).  Gels were transferred to PVDF membranes and
probed with anti-V5 antibody (Invitrogen).
Growth Analysis of Toxicity
For OD600 analysis, absorbance readings of yeast cells
expressing a-synuclein were taken at 600nm using a Hitachi U-
200 spectrophotometer at 0, 3, 6, 12, 18, 24, and 36 hours after
induction.  For spotting, yeast cells were grown in SC-
ura+glucose to mid-log phase, washed with H2O, and then
resuspended in SC-ura+raffinose for 4 hours.  Cell densities
were normalized and a dilution series of 6, 1:10 serial dilutions
were made for each sample.  These dilution series were
spotted on SC-ura+galactose plates. Cells were photographed
after 2 days of growth.
Loss of Induction
Yeast cells grown in SC-ura+glucose media overnight were
washed in H2O and resuspended in SC-ura+galactose media to
induce α-synuclein expression.  After 18 hours of induction,
cells were transferred back to SC-ura+glucose media, halting
the further synthesis of α-synuclein.  At 0, .5, 1, 2, 4, 6, 9, 12,
18, and 24 hours after the shut off of α-synuclein synthesis,
whole cell lysates were made from each strain, and a Western
blot using α-synuclein antibody was performed.
GFP Microscopy
Vps28 yeast cells were visualized under blue-filter settings
using a Zeiss Axiovert-100 fluorescent microscope 18-24 hours
after galactose-induced α-synuclein expression.  Images were
acquired with Metamorph 4.0 imaging software.
Correspondingly transformed 4741 strains were visualized as a
control and used as the basis for α-synuclein distribution and
accumulation when a functioning MVB sorting pathway is
present.
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